Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937290 | 0.81 | MCHR1 (0.46) | S1PR4MEN1KMT2ACYP19A1GRIN1 | |
| SCHEMBL25937265 | 0.72 | HTR2A (0.33) | — | |
| SCHEMBL25937266 | 0.71 | HTR2C (0.36) | — | |
| SCHEMBL20116703 | 0.70 | S1PR4 (0.55) | S1PR4KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL25937262 | 0.69 | SCD (0.34) | KDM4E | |
| SCHEMBL25937264 | 0.69 | S1PR5 (0.31) | — | |
| SCHEMBL20325702 | 0.68 | ROCK1 (0.43) | KDM4EMEN1ALDH1A1KMT2AATM | |
| SCHEMBL30564402 | 0.68 | HPGD (0.38) | S1PR4KDM4EMEN1ALDH1A1TP53 | |
| SCHEMBL25937316 | 0.68 | MCHR1 (0.41) | CYP19A1MCHR1 | |
| SCHEMBL23207657 | 0.67 | HSD17B10 (0.39) | KDM4EHCRTR2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310423-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF | CHEK1, CHEK2, RAD1 | S1PR4 2246/4885ENPP2 3460/4885KDM4E 1925/4885 |
| US-11707462-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, CHEK2, RAD1 | S1PR4 2246/4885ENPP2 3460/4885KDM4E 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.